Two hours of darkness can push a plant's daily clock earlier, later or not at all, depending on the hour. A team including @umichkim used a neural network on old glow recordings to map that sensitivity hour by hour, then predict what longer nights would do.
An atlas of about 375,000 vessel-lining cells from 12 human tissues, published in @NatureAging, finds that with age inflammation genes rise in every tissue while each organ adds its own changes, and veins lose the most of the genes that grow new vessels.
Aging researcher Saul Newman, in an AMA opened by @mitpress for his book Morbid, says a supplement that truly slowed aging would show up in an ordinary trial: an eight-year rewind needs about 460 people per group. A small slowing would need millions, or real illness counted.
Former OpenAI executive @kevinweil and co-founders raised $215 million for @warpsciences, a US lab that makes and tests drug molecules for other companies and records every step so AI can learn from real experiments. It owns no drug, and its speed is still unshown.
In adults a DNA risk score can be checked step by step: it led to statins, lower LDL and fewer heart events in a small trial. Ranking IVF embryos by the same math, notes geneticist @YaronMD, can be checked only decades later, and @ASRM_org calls it unproven.
Squeezing the shin bones of old mice twice a week, with no exercise at all, raised their median lifespan by about 80 days, a study in @Cell_Metabolism reports, and bone that senses force appears to send a signal through the blood that shifts aging far from the shin.
Asked by @tylercowen whether AI for longevity deserves Moon-shot funding, White House science chief @mkratsios47 said it is not a top national priority and is for @NIH to explore; first comes a shared AI platform for all science. No aging program or budget was announced.
AI can now draw drug molecules fast, but @VasNarasimhan of @Novartis argues it should be judged by approvals: about 8 in 100 programs entering human trials win one today. @DaphneKoller of @insitro adds that the hard part is knowing which process in the body drives a disease.
After melanoma surgery, 82% of patients given an mRNA medicine built from their own tumor's mutations plus pembrolizumab stayed free of recurrence at two years, against 70% on pembrolizumab alone, @Merck and @moderna_tx report from a Phase III trial of about 1,100 adults.
A perspective in @FrontScience maps cell-surface receptors whose balance shifts with age and proposes testing drug combinations to push them back. A viewpoint alongside names the gap: the map says which receptors, not whether to switch each one on or block it in aging tissue.